Gnetifolin E

CAS No. 140671-07-4

Gnetifolin E( —— )

Catalog No. M37781 CAS No. 140671-07-4

Gnetifolin E is a new resveratrol trimer derivative from Gnetum brunonianum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 1055 In Stock
5MG 1055 In Stock
10MG 1406 In Stock
25MG 2119 In Stock
50MG 2734 In Stock
100MG 3692 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Gnetifolin E
  • Note
    Research use only, not for human use.
  • Brief Description
    Gnetifolin E is a new resveratrol trimer derivative from Gnetum brunonianum.
  • Description
    Gnetifolin E is a resveratrol trimer derivative that can be isolated from Gnetum brunonianum. Gnetifolin E has anti-inflammatory activity, and inhibits TNF-α.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    140671-07-4
  • Formula Weight
    420.41
  • Molecular Formula
    C21H24O9
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O(C1=C(OC)C=C(/C=C/C2=CC(O)=CC(O)=C2)C=C1)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yao CS, et al. A new resveratrol trimer derivative from Gnetum brunonianum. J Asian Nat Prod Res. 2012;14(9):918-22.?
molnova catalog
related products
  • LDN-212320

    LDN-212320 is a glutamate transporter EAAT2 activator. It also enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.

  • IL-8 Inhibitor

    Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury.

  • KT-474

    KT-474 (KYM-001) is a PROTAC degrader targeting interleukin-1 receptor-associated kinase 4 (IRAK4) with antitumor activity for the study of autoimmune, inflammatory, and cardiovascular disease disorders.